Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine [Phase 3]

View source ↗

Summary

Phase 3 study evaluating intravenous eptinezumab for acute migraine attacks has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• EptinezuMaB

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2021-08-16